IBT
FULC icon

International Biotechnology Trust’s Fulcrum Therapeutics FULC Stock Holding History

International Biotechnology Trust’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-193,741
Closed -$1.41M – 67
2022
Q4 		$1.41M Hold
193,741
– – 0.44% 41
2022
Q3 		$1.56M Buy
193,741
+192,792
+20,315% +$1.38M 0.5% 45
2022
Q2 		$194K Sell
949
-81,792
-99% -$799K 2.02% 18
2022
Q1 		$833K Buy
82,741
+21,741
+36% +$308K 0.19% 59
2021
Q4 		$1.08M Buy
+61,000
New +$1.21M 0.24% 57

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

International Biotechnology Trust's FULC Position: Q1 2023 in Review

International Biotechnology Trust sold out of Fulcrum Therapeutics (FULC) in Q1 2023, closing a stake of 193,741 shares — an estimated $1.41M sold.

International Biotechnology Trust first reported a position in FULC in Q4 2021 and held it in 5 quarters. The position peaked at $1.56M in Q3 2022. 116 funds tracked by Wall St. Rank hold FULC as of Q1 2023.

  • International Biotechnology Trust reported no remaining Fulcrum Therapeutics position as of Q1 2023 after selling out during the quarter.
  • International Biotechnology Trust sold 193,741 Fulcrum Therapeutics shares in Q1 2023, an estimated $1.41M.
  • International Biotechnology Trust first reported a position in Fulcrum Therapeutics in Q4 2021 and held it in 5 quarters.
  • International Biotechnology Trust's Fulcrum Therapeutics position peaked at $1.56M in Q3 2022.
  • 116 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2023.

Based on International Biotechnology Trust's 13F filing for Q1 2023, filed 18 May 2023.